Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Elevance Health (ELV) is back in focus after a 6% share price jump following the release of 2027 Medicare payment rates by the Centers for Medicare & Medicaid Services, alongside a broader rally in managed care stocks.
See our latest analysis for Elevance Health.
That CMS catalyst sits against a tougher backdrop, with a 1 year total shareholder return decline of 26.1% and a 3 month share price return decline of 15%, so the recent 7.7% 1 month share price gain suggests momentum is rebuilding as investors reassess earnings risk.
If you are looking beyond managed care and want to see where capital is shifting in adjacent healthcare themes, now is a useful moment to scan 37 healthcare AI stocks
With Elevance Health now trading at $311.83, sitting at a discount to the average analyst price target and with an intrinsic value estimate that suggests further upside, is the recent weakness a reset worth considering, or is the market already pricing in future growth?
According to the most followed narrative, Elevance Health’s fair value sits at $390.54 per share, comfortably above the last close at $311.83. This frames the recent rebound in a very different light.
As a potential growth investment, Elevance Health offers a mix of undervaluation and long-term growth drivers, particularly in the Medicare Advantage and value-based care segments. While near-term risks like Medicaid enrollment declines and cost pressures pose challenges, its diversified revenue base and focus on innovation provide resilience. Strategic timing and close monitoring of market and operational trends will be essential to evaluating its growth potential over the next 1-3 years.
Curious what underpins a fair value almost $80 above today’s price? The narrative focuses on earnings power, margin repair, and a future profit multiple that assumes Elevance is priced closer to sector leaders than recent returns suggest.
Result: Fair Value of $390.54 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this depends on Medicaid pressures and elevated medical costs easing. Continued membership losses or persistently high claims could keep returns under pressure.
Find out about the key risks to this Elevance Health narrative.
With sentiment leaning cautiously optimistic, this is a good moment to review the numbers yourself and stress test the assumptions behind the bullish case. To see what investors are currently focused on, start with the 5 key rewards
